Seelos Therapeutics, Inc. (SEEL)
After hours:
Chart Events
Performance Outlook
| Previous Close | 0.8678 |
| Open | 0.8600 |
| Bid | 0.8301 x 2200 |
| Ask | 0.8810 x 1100 |
| Day's Range | 0.8300 - 0.8998 |
| 52 Week Range | 0.4800 - 1.5200 |
| Volume | |
| Avg. Volume | 637,677 |
| Market Cap | 90.246M |
| Beta (5Y Monthly) | 1.96 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.6090 |
| Earnings Date | Aug 05, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 6.25 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for SEEL
Related Research
- Seelos Therapeutics, Inc.Analyst Report: Eli Lilly and CompanyEli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Jardiance, Trulicity, Humalog, and Humulin for diabetes; and Taltz and Olumiant for immunology.RatingFair ValueEconomic Moat2 days agoMorningstar
- PR Newswire
Seelos Therapeutics to Participate in the 12th Annual LifeSci Partners Corporate Access Event
Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced that it will participate in the 12th Annual LifeSci Partners Corporate Access Event, to be held in San Francisco, California on January 9-11th, 2023.
- Benzinga
Parkinson's Study Using CRISPR Technology Shows Promise, Seelos Therapeutics Says
Seelos Therapeutics Inc (NASDAQ: SEEL) announced in vivo data demonstrating that a single dose of SLS-004 downregulated the production of alpha-synuclein (α-synuclein). This reduction of α-synuclein by SLS-004 in an established α-synuclein overexpressing animal model of Parkinson's disease (PD) resulted in a substantial increase and recovery of degeneration in tyrosine hydroxylase positive (TH+) dopaminergic neurons. TH+ dopaminergic neurons in the midbrain region, called substantia nigra pars c
- PR Newswire
Seelos Therapeutics Announces Data Demonstrating Downregulation of Alpha Synuclein in an In Vivo Gene Therapy Study of SLS-004 Utilizing CRISPR-dCas9 in Parkinson's Disease
Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced in vivo data demonstrating that a single dose of SLS-004 downregulated the production of alpha-synuclein (α-synuclein). This reduction of α-synuclein by SLS-004 in an established α-synuclein overexpressing animal model of Parkinson's disease (PD) resulted in substantial increase and recovery of degener
